Method of enhancing TGF-β signalling
View Patent ↗The present invention is directed to a method of enhancing TGF-β signaling in a subject comprising administering to said subject a clathrin-dependent endocytosis inhibitor in an amount sufficient to enhance TGF-β signaling. In another aspect, the invention is directed to a method of treating a condition associated with decreased TGF-β signaling in a patient in need thereof comprising administering to said patient a clathrin-dependent endocytosis inhibitor in a therapeutically effective amount.
1. A method of accelerating wound healing in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a clathrin-dependent endocytosis inhibitor, wherein the clathrin-dependent endocytosis inhibitor is dynasore.
2. A method of treating cardiovascular disease in a patient in need thereof comprising administering to said patient a clathrin-dependent endocytosis inhibitor in a therapeutically effective amount, wherein the clathrin-dependent endocytosis inhibitor is dynasore.
3. A method of treating atherosclerosis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of dynasore.
4. The method of claim 3 , further comprising administration of a therapeutically effective amount of a statin.
5. The method of claim 4 , wherein the statin is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, itavastatin, rosuvastatin and rivastatin.
6. A method of treating a skin condition characterized by decreased TGF-beta signaling selected from the group consisting of psoriasis, basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, actinic keratosis, C-linked ichthyosis, acne, dermatitis and epidermolytic hyperkeratosis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of dynasore.
7. A pharmaceutical composition comprising a therapeutically effective amount of dynasore, a therapeutically effective amount of a statin and a pharmaceutically acceptable carrier.
8. The composition of claim 7 , wherein the statin is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, itavastatin, rosuvastatin and rivastatin.